EXACT SCIENCES CORPORATION (NASDAQ:EXAS) Files An 8-K Other Events

ME Staff 8-k
-
0

EXACT SCIENCES CORPORATION (NASDAQ:EXAS) Files An 8-K Other Events
Item 8.01 Other Matters.

On June29, 2017, the underwriters of the Company’s previously announced public offering (the “Offering”) partially exercised their over-allotment option by purchasing an additional 450,000 shares of the Company’s common stock at a price to the public of $35.00 per share, resulting in net proceeds to the Company of approximately $15.4 million, and bringing the total net proceeds raised by the Company in the Offering to approximately $253.4 million, in each case, after deducting underwriting discounts and commissions.


About EXACT SCIENCES CORPORATION (NASDAQ:EXAS)

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

EXACT SCIENCES CORPORATION (NASDAQ:EXAS) Recent Trading Information

EXACT SCIENCES CORPORATION (NASDAQ:EXAS) closed its last trading session down -0.94 at 34.43 with 948,523 shares trading hands.